TIDMHIK 
 
RNS Number : 0219K 
Hikma Pharmaceuticals Plc 
12 April 2010 
 

 
            Hikma expands its manufacturing capabilities in Algeria 
 
LONDON, 12 April 2010 - Hikma Pharmaceuticals PLC ("Hikma")(LSE: HIK, NASDAQ 
Dubai: HIK), the fast growing multinational pharmaceutical group, announces that 
 its wholly-owned subsidiary, Arab Pharmaceutical Manufacturing Company ('APM'), 
has signed an agreement to acquire the 50% stake that it did not previously own 
in the Algerian company Al Dar Al Arabia Pharmaceutical Manufacturing Company 
("Al Dar Al Arabia") from the Jordanian pharmaceutical company, Dar Al Dawa, for 
a consideration of $18.5 million. 
 
 Al Dar Al Arabia was established in 2005 as a joint venture between APM, a 
wholly-owned subsidiary of Hikma, and Dar Al Dawa.  The company owns a 6,000 m2 
manufacturing facility that has recently been constructed to the highest 
international standards and approximately 21,000 m2 of land in an industrial 
zone in Algiers.  Once operational, the Al Dar Al Arabia plant will double 
Hikma's manufacturing capacity in Algeria and will provide significant scope for 
further expansion. 
 
Algeria is the second largest pharmaceutical market in the MENA region. 
Following recent changes to regulations that encourage local production, it has 
become increasingly important for Hikma to expand its manufacturing capabilities 
in this country.  The acquisition will facilitate the expansion of Hikma in 
Algeria and will help to meet the rapidly growing demand for high quality drugs 
in the MENA region. 
 
 The transaction is conditional upon the satisfaction of various legal 
requirements and official procedures and is expected to close at the end of June 
2010.  The acquisition will be funded by existing cash resources. 
 
=- ENDS -- 
 
Enquiries 
Hikma Pharmaceuticals PLC 
Susan Ringdal, Investor Relations Director          Tel: +44 (0)20 7399 2760 
 
Brunswick Group 
Jon Coles / Justine McIlroy                                          Tel: +44 
(0)20 7404 5959 
 
 
About Hikma 
Hikma Pharmaceuticals PLC is a fast growing multinational group focused on 
developing, manufacturing and marketing a broad range of both branded and 
non-branded generic and in-licensed  products.  Hikma's operations are conducted 
through three businesses: "Branded", "Injectables" and "Generics" based 
principally in the Middle East and North Africa ("MENA") region, where it is a 
market leader, the United States and Europe.  In 2009, Hikma achieved revenues 
of $637 million and profit attributable to shareholders of $78 million.  For 
news and other information, please visit www.hikma.com. 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 ACQGIGDSDBBBGGD
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Hikma Pharmaceuticals Charts.
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Hikma Pharmaceuticals Charts.